5-HT2C ligands: recent progress.
Monck
Nathaniel J T
NJ
Vernalis (R&D) Ltd., 613 Reading Road, Winnersh, Wokingham, Berkshire, RG41 5UA, UK.
Kennett
Guy A
GA
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D008024:Ligands; D001523:Mental Disorders / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy; D044405:Receptor, Serotonin, 5-HT2C / Q000378:metabolism*; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D013329:Structure-Activity Relationship
D019440:Anti-Obesity Agents; D014150:Antipsychotic Agents; D008024:Ligands; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists